The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 25, 2023
Filed:
Mar. 06, 2019
Unm Rainforest Innovations, Albuquerque, NM (US);
The United States of America, As Represented BY the Secretary, Department of Health and Human Services, Bethesda, MD (US);
Bryce Chackerian, Albuquerque, NM (US);
Alan Remaley, Bethesda, MD (US);
Marcelo Amar, Bethesda, MD (US);
Alexandra Fowler, Albuquerque, NM (US);
Bryce Chackerian, Albuquerque, NM (US);
Alan Remaley, Bethesda, MD (US);
Marcelo Amar, Bethesda, MD (US);
Alexandra Fowler, Albuquerque, NM (US);
UNM Rainforest Innovations, Albuquerque, NM (US);
The United States of America, as represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US);
Abstract
An immunogen generally includes a virus-like particle and an antigen linked to the virus-like particle. The antigen includes an antigenic portion of a polypeptide, wherein the polypeptide inhibits lipoprotein lipase (LPL) activity by binding to LPL. In some embodiments, the polypeptide is at least a portion of angiopoietin-like 3 (ANGPTL3). In other embodiments, the polypeptide is at least a portion of angiopoietin-like 4 (ANGPTL4). In other embodiments, the polypeptide at least a portion of angiopoietin-like 8 (ANGPTL8). In some embodiments, the virus-like particle is a Qbeta immunogenic carrier. In some of these embodiments, the antigen is linked to the virus-like particle through a Gly-Gly-Gly-Cys linker at the C-terminal of the antigen.